BD receives CE mark for liver disease stent graft in Europe
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
BD Delivers Next‑Generation TIPS Innovation to Advance Portal Hypertension Care Across the European Union
April 8, 2026 6:50 AM EDTCE Marking and ARCH clinical trial data position the Liverty TIPS Stent Graft to expand treatment options for patients with advanced liver disease
FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced application of CE Mark for the Liverty TIPS Stent Graft, delivering innovation to portal hypertension care across the European Union. Designed to expand treatment options for... More
